Activated Protein C Resistance in Type I Diabetes
Gabriella Gruden(University of Turin), Gianfranco Pagano(University of Turin), C. Olivetti(University of Turin), Stefania Stella(University of Catania), P. Cavallo‐Perin, Mario Bazzan(Ospedale San Giovanni Bosco), G. Tamponi(Istituto di Ematologia di Bologna)
Cited by 16
Related Papers
Three Months versus One Year of Oral Anticoagulant Therapy for Idiopathic Deep Venous Thrombosis
|New England Journal of Medicine|2001|599
Enoxaparin for the Prevention of Venous Thromboembolism Associated With Central Vein Catheter: A Double-Blind, Placebo-Controlled, Randomized Study in Cancer Patients
|Journal of Clinical Oncology|2005|305
Risk factors for upper limb deep vein thrombosis associated with the use of central vein catheter in cancer patients
|Internal and Emergency Medicine|2008|126
Impact of residual pulmonary obstruction on the long-term outcome of patients with pulmonary embolism
|European Respiratory Journal|2017|123
Fondaparinux-related thrombocytopenia in a previous low-molecular-weight heparin (LMWH)-induced heparin-induced thrombocytopenia (HIT)
|Thrombosis and Haemostasis|2008|121